Viking Therapeutics is developing novel therapeutics for patients suffering from metabolic and endocrine disorders.
Viking Therapeutics has raised $632.5M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in February 2024.
Viking Therapeutics's investors include Ligand Pharmaceuticals, Aspire Capital Partners LLC.
Viking Therapeutics is headquartered in San Diego, United States.
Viking Therapeutics is developing novel therapeutics for patients suffering from metabolic and endocrine disorders.
Viking Therapeutics is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Viking Therapeutics — Funding & Investors." VCBacked, February 28, 2024, https://www.vcbacked.co/company/viking-therapeutics. Accessed September 30, 2026.
VCBacked. (2024). Viking Therapeutics — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/viking-therapeutics
{{cite web |title=Viking Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/viking-therapeutics |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated